Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 679 Shares

Posted by Brian Himes on Sep 1st, 2026

Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) insider Mittie Doyle sold 679 shares of Avalo Therapeutics stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $20.00, for a total transaction of $13,580.00. Following the completion of the sale, the insider owned 51,776 shares of the company’s stock, valued at approximately $1,035,520. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

On Monday, July 27th, Mittie Doyle sold 1,000 shares of Avalo Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $20,000.00.
On Tuesday, June 23rd, Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock. The stock was sold at an average price of $18.00, for a total value of $26,100.00.

Avalo Therapeutics Stock Down 2.0%

Shares of NASDAQ:AVTX traded down $0.39 during trading on Tuesday, reaching $18.95. 606,643 shares of the company traded hands, compared to its average volume of 1,150,310. The company’s 50 day moving average is $19.03 and its two-hundred day moving average is $16.82. The firm has a market capitalization of $1.02 billion, a PE ratio of -4.34 and a beta of 0.80. Avalo Therapeutics, Inc. has a 52 week low of $8.65 and a 52 week high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.25). As a group, research analysts anticipate that Avalo Therapeutics, Inc. will post -2.59 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on AVTX. BTIG Research reissued a “buy” rating and set a $58.00 price objective on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Leerink Partners began coverage on Avalo Therapeutics in a research note on Monday, July 6th. They set an “outperform” rating and a $38.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Avalo Therapeutics in a research note on Friday, July 24th. Citigroup reiterated an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Finally, Bank of America began coverage on shares of Avalo Therapeutics in a report on Friday, June 12th. They set a “buy” rating and a $35.00 target price on the stock. Thirteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $45.10.

Check Out Our Latest Stock Analysis on AVTX

Hedge Funds Weigh In On Avalo Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Braidwell LP acquired a new position in shares of Avalo Therapeutics in the second quarter worth approximately $30,107,000. Caligan Partners LP acquired a new stake in Avalo Therapeutics during the 3rd quarter valued at approximately $10,592,000. Balyasny Asset Management L.P. bought a new position in Avalo Therapeutics during the 3rd quarter worth approximately $10,390,000. Vanguard Group Inc. raised its holdings in Avalo Therapeutics by 314.9% during the 3rd quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock worth $8,803,000 after purchasing an additional 525,696 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of Avalo Therapeutics by 380.2% in the 4th quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock worth $11,985,000 after purchasing an additional 522,548 shares during the period. 87.06% of the stock is currently owned by institutional investors.

About Avalo Therapeutics

(Get Free Report)

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.